Stabilitech, founded in 2002 by Dr. Jeff Drew, is a privately-owned enterprise based in the London Bioscience Innovation Centre, dedicated to stabilizing sensitive biological molecules, including vaccines and biopharmaceuticals. The company's mission revolves around enhancing the stability of these critical components through proprietary formulation technology. This innovative approach ensures the long-term stability of various thermally sensitive viruses, vaccines, and biopharmaceuticals. Notably, the compositions consist of chemical ingredients already approved for clinical use, either as injectables or listed as Generally Regarded As Safe (GRAS). Stabilitech's strategic focus is on commercializing its technology through partnerships with major pharmaceutical and biotechnology firms, as well as global health organizations. In August 2011, the company secured a significant $3.50M Series C investment.
General Information
Get notified when Stabilitech moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Stabilitech
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About Stabilitech
Taxonomy: biopharmaceuticals, vaccines, stabilization technology, thermally sensitive viruses, formulation technology, biological molecules, drug stability, pharmaceutical partnerships, global health organizations
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | •••••• | - | 06 Aug 2011 | |
| Debt Financing | •••••• | - | 13 May 2011 | |
| Venture Round | •••••• | - | 12 Mar 2009 |
Stabilitech Alternatives & Competitors
Enhance protein-based drug discovery with rapid optimization of solubility and stability using our h...
Delivering next-generation nanovaccines and biopharmaceuticals faster for global health protection.
Discover the Power of Insulation
FAQ About Stabilitech
Don't just browse. Track.
Signal Tracker monitors Stabilitech and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.